Cardiovascular drugs and COVID‐19 clinical outcomes: a living systematic review and meta‐analysis

Review (819 studies) found ACEI/ARB exposure was not associated with confirmed COVID-19 infection (OR 0.92, 0.71–1.19), hospitalisation (0.93, 0.70–1.24), disease severity (1.05, 0.81–1.38), or all-cause mortality (0.84, 0.70–1.00) in adjusted analyses.

Source:

British Journal of Clinical Pharmacology